Meeting
2024 ASCO Genitourinary Cancers Symposium
A meta-analysis assessing objective response rates with first-line systemic treatment options in locally advanced/metastatic urothelial carcinoma.
Authors
Akshat Saxena
Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
Akshat Saxena , Syed Arsalan Ahmed Naqvi , Nikita Tripathi , Muhammad Ali Khan , Arifa Bibi , Tara Ballouz , Haidar Abdul-Muhsin , Mark Tyson , Irbaz Bin Riaz , Alan Haruo Bryce , Parminder Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 639)
DOI
10.1200/JCO.2024.42.4_suppl.639
Abstract #
639
Poster Bd #
J3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).
First Author: Syed Arsalan Ahmed Naqvi
Poster
2022 ASCO Annual Meeting
A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.
First Author: Bo Yang
Poster
2022 ASCO Genitourinary Cancers Symposium
Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study.
First Author: Shilpa Gupta
Poster
2022 ASCO Genitourinary Cancers Symposium
Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC).
First Author: Lisa Bloudek